CA3061206A1 - Constructions ameliorees de lamp - Google Patents

Constructions ameliorees de lamp Download PDF

Info

Publication number
CA3061206A1
CA3061206A1 CA3061206A CA3061206A CA3061206A1 CA 3061206 A1 CA3061206 A1 CA 3061206A1 CA 3061206 A CA3061206 A CA 3061206A CA 3061206 A CA3061206 A CA 3061206A CA 3061206 A1 CA3061206 A1 CA 3061206A1
Authority
CA
Canada
Prior art keywords
improved lamp
cells
cell
lamp
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3061206A
Other languages
English (en)
Inventor
Teri Heiland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomic Therapeutics Inc
Original Assignee
Immunomic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics Inc filed Critical Immunomic Therapeutics Inc
Publication of CA3061206A1 publication Critical patent/CA3061206A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des constructions améliorées de LAMP comprenant des fragments spécifiques du domaine luminal LAMP pour administrer des antigènes à des cellules immunitaires en vue d'un traitement amélioré. Les constructions LAMP de l'invention peuvent être utilisées pour le traitement de maladies et, en particulier, d'allergies, d'une maladie infectieuse, du diabète, de troubles hyperprolifératifs et/ou du cancer. Les constructions améliorées de LAMP permettent la présentation d'épitopes tridimensionnels correctement configurés pour la production d'une réponse immunitaire lorsqu'ils sont administrés à un sujet. Les constructions améliorées de LAMP peuvent être des molécules multivalentes et/ou peuvent être fournis en tant que partie d'un vaccin multivalent comprenant au moins deux constructions de LAMP. Les constructions améliorées de LAMP de la présente invention peuvent également être utilisées pour générer des anticorps lorsqu'elles sont administrées à un vertébré non humain.
CA3061206A 2017-04-22 2018-04-22 Constructions ameliorees de lamp Pending CA3061206A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762488741P 2017-04-22 2017-04-22
US62/488,741 2017-04-22
US201762549119P 2017-08-23 2017-08-23
US201762549033P 2017-08-23 2017-08-23
US62/549,033 2017-08-23
US62/549,119 2017-08-23
PCT/US2018/028753 WO2018195527A1 (fr) 2017-04-22 2018-04-22 Constructions améliorées de lamp

Publications (1)

Publication Number Publication Date
CA3061206A1 true CA3061206A1 (fr) 2018-10-25

Family

ID=62223207

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3061206A Pending CA3061206A1 (fr) 2017-04-22 2018-04-22 Constructions ameliorees de lamp

Country Status (9)

Country Link
US (3) US11203629B2 (fr)
EP (1) EP3612556A1 (fr)
JP (3) JP2020517271A (fr)
KR (1) KR102637960B1 (fr)
CN (1) CN110799529A (fr)
AU (2) AU2018254776B2 (fr)
BR (1) BR112019022108A2 (fr)
CA (1) CA3061206A1 (fr)
WO (1) WO2018195527A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240027895A (ko) * 2017-05-02 2024-03-04 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
JP2021523185A (ja) * 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
AU2020366515A1 (en) * 2019-10-18 2022-04-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
WO2022099695A1 (fr) * 2020-11-16 2022-05-19 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Fusion cd164 et leurs utilisations
WO2023201201A1 (fr) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Constructions de lamp bicistroniques comprenant des gènes améliorant la réponse immunitaire et leurs procédés d'utilisation

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US55458A (en) 1866-06-12 Aldee beigham
US4237115A (en) 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4397844A (en) 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2026340B (en) 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
US4681762A (en) 1979-05-23 1987-07-21 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4593002A (en) 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4592002A (en) 1983-12-13 1986-05-27 Honeywell Inc. Method of digital temperature compensation and a digital data handling system utilizing the same
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
EP0247091B1 (fr) 1985-11-01 1993-09-29 Xoma Corporation Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
EP0394827A1 (fr) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
EP0739904A1 (fr) 1989-06-29 1996-10-30 Medarex, Inc. Réactifs bispécifiques pour le traitement du SIDA
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3583420B2 (ja) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
DE69128253T2 (de) 1990-10-29 1998-06-18 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
JP3431140B2 (ja) 1991-04-26 2003-07-28 サーフィス・アクティブ・リミテッド 抗体およびその使用方法
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5661133B1 (en) 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1993017715A1 (fr) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Agents diagnostiques et/ou therapeutiques cibles sur des cellules endotheliales neovasculaires
WO1994010958A1 (fr) 1992-11-13 1994-05-26 Mitchell Winalee G Dispositif de controle de capacite avec materiau superabsorbant et noyau absorbant
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
DE699079T1 (de) 1994-03-07 1997-09-25 Dendritech Inc Bioaktive und/oder gezielte dendrimere-konjugate
WO1995028494A1 (fr) 1994-04-15 1995-10-26 Targeted Genetics Corporation Proteine de fusion d'apport de gene
FR2719316B1 (fr) 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
US5972707A (en) 1994-06-27 1999-10-26 The Johns Hopkins University Gene delivery system
EP0769063A1 (fr) 1994-06-27 1997-04-23 The Johns Hopkins University Systeme de transport de gene cible
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
DE69627820T2 (de) 1995-01-17 2004-04-08 The Brigham And Women's Hospital Inc., Boston Rezeptorspezifischer transepithelialer transport von immunogenen
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
WO1997035996A1 (fr) 1996-03-25 1997-10-02 Transgene S.A. Lignee cellulaire d'encapsidation a base de cellules 293 humaines
CZ438398A3 (cs) 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (fr) 1996-12-03 2014-05-07 Amgen Fremont Inc. Mammifères transgèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus
DE69739961D1 (de) 1996-12-13 2010-09-23 Schering Corp Methoden zur Virus-Reinigung
FR2760193B1 (fr) 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
FR2763958A1 (fr) 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
WO1998056370A2 (fr) 1997-06-13 1998-12-17 Johns Hopkins University School Of Medicine Nanospheres therapeutiques
AU707186B2 (en) 1997-07-01 1999-07-01 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
US6511832B1 (en) 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
DK1385538T3 (da) 2001-04-05 2013-04-29 Univ Johns Hopkins Kimære vacciner omfattende det lumenale domæne fra LAMP-1 eller LAMP-2
US20070269457A1 (en) 2006-05-16 2007-11-22 The Buck Institute For Age Research Immunotherapeutic compositions and methods
EP2161279A1 (fr) * 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Peptides synthétiques correspondant à des déterminants de neutralisation chevauchant dans l'épitope CBD1 induisant des anticorps largement neutralisants
EA201592264A1 (ru) 2009-08-26 2016-08-31 Селекта Байосайенсиз, Инк. Композиции, которые индуцируют хелперное действие т-клеток
WO2011046996A2 (fr) * 2009-10-13 2011-04-21 The Johns Hopkins University Séquence consensus pour le virus de la grippe a
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
SI2861240T1 (sl) * 2012-06-15 2021-04-30 Immunomic Therapeutics, Inc. Nukleinske kisline za zdravljenje alergij
BR112016030439A2 (pt) 2014-06-23 2018-07-17 Immunomic Therapeutics Inc ácidos nucléicos para o tratamento de alergias ao amendoim.
EP3328394A4 (fr) * 2015-07-30 2019-03-13 ModernaTX, Inc. Arn épitope peptidiques concatémériques

Also Published As

Publication number Publication date
JP7486566B2 (ja) 2024-05-17
KR20200018777A (ko) 2020-02-20
JP2020517271A (ja) 2020-06-18
BR112019022108A2 (pt) 2020-05-12
EP3612556A1 (fr) 2020-02-26
US20200377570A1 (en) 2020-12-03
US20220153809A1 (en) 2022-05-19
US11203629B2 (en) 2021-12-21
US20240092864A1 (en) 2024-03-21
JP2023015342A (ja) 2023-01-31
CN110799529A (zh) 2020-02-14
WO2018195527A1 (fr) 2018-10-25
AU2022241594B2 (en) 2023-11-23
AU2018254776B2 (en) 2022-06-30
AU2018254776A1 (en) 2019-10-31
JP2024056912A (ja) 2024-04-23
AU2022241594A1 (en) 2022-12-08
US11773153B2 (en) 2023-10-03
KR102637960B1 (ko) 2024-02-21

Similar Documents

Publication Publication Date Title
US11773153B2 (en) LAMP constructs
JP7407902B2 (ja) 癌抗原を含む改善されたｌａｍｐ構築物
US20240108703A1 (en) Improved LAMP Constructs Comprising Cancer Antigens
US20210261647A1 (en) Lamp constructs comprising allergens

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220915

EEER Examination request

Effective date: 20220915

EEER Examination request

Effective date: 20220915

EEER Examination request

Effective date: 20220915

EEER Examination request

Effective date: 20220915